United States News All stories

Hafnia (NYSE:HAFN) has significantly expanded its long-term capacity, announcing a $405 million contract with Hyundai Heavy Industries for the construction of eight new Medium-Range (MR) product tankers.

Algorhythm Holdings (NASDAQ:RIME) reported a dramatic expansion in its top-line performance for fiscal year 2025, driven by the successful integration of its Indian logistics acquisition and a significant restructuring of its balance sheet.

Fusion Fuel (NASDAQ:HTOO) highlighted a pivotal fiscal 2025 for its majority-owned subsidiary, Quality Industrial Corp (QIND), as the unit successfully cleared legacy financial hurdles while posting double-digit top-line growth.

CME Group (NASDAQ:CME) reported the highest monthly and quarterly trading volumes in its history, as a surge in interest rate and energy market activity propelled the world’s largest derivatives exchange to new heights in early 2026.

Soligenix (NASDAQ:SNGX) announced the peer-reviewed publication of clinical data today, reinforcing the potential of its lead candidate, HyBryte™, to provide a safer and more effective alternative to the current standard of care for early-stage cutaneous T-cell lymphoma (CTCL).

AngioDynamics (NASDAQ:ANGO) reported its financial results for the third quarter of fiscal year 2026, ended February 28, 2026, on Thursday, April 2.

Novo Nordisk (NYSE:NVO) has intensified its rivalry with Eli Lilly (NYSE:LLY), releasing a provocative cross-trial analysis that claims its experimental Wegovy pill is both more effective and better tolerated than Lilly’s recently approved obesity tablet, Foundayo.

ECARX Holdings (NASDAQ:ECX) achieved a historic financial turning point in the final months of 2025, reporting its first-ever quarterly net income as a public company alongside a surge in shipments for its flagship automotive computing platforms.

Tesla (NASDAQ:TSLA) reported first-quarter delivery numbers that fell short of Wall Street expectations, raising fresh concerns about a widening gap between the electric vehicle maker's manufacturing pace and global consumer appetite.

Innovative Aerosystems (NASDAQ:ISSC) has reached an agreement with Honeywell International (NASDAQ:HON) to acquire key assets and intellectual property for select legacy avionics lines, a move that deepens the company’s reach into the global general aviation market.

Merck (NYSE:MRK) has secured a landmark regulatory approval in the European Union for its blockbuster immunotherapy Keytruda, marking the region’s first PD-1 inhibitor authorized to treat a particularly aggressive form of ovarian cancer.

Adagene (NASDAQ:ADAG) reported updated clinical data for its lead "SAFEbody" candidate, muzastotug, revealing a significant dose-dependent response in patients with treatment-resistant colorectal cancer—a population that has traditionally been unresponsive to immunotherapy.

Classover (NASDAQ:KIDZ), an AI-powered education technology company, reported its full-year 2025 financial results.

Namib Minerals (NASDAQ:NAMM) reported a resilient fiscal 2025 performance, characterized by rising profitability and steady progress on its multi-asset growth strategy in Zimbabwe, despite a slight dip in annual gold production.

ScottsMiracle-Gro (NYSE:SMG) has reaffirmed its fiscal 2026 financial guidance, signaling confidence in its margin recovery plan by highlighting a supply chain largely insulated from international volatility and inflationary spikes.

Adagene (NASDAQ:ADAG) and Incyte (NASDAQ:INCY) have entered into a clinical trial collaboration to evaluate a potent combination of immunotherapy agents in patients with microsatellite stable colorectal cancer (MSS CRC), a disease state notoriously resistant to standard immune checkpoint inhibitors.

AstraZeneca (NASDAQ:AZN) announced positive high-level results from its EMERALD-3 Phase III trial, demonstrating that a novel combination of immunotherapies and targeted treatment significantly improved outcomes for patients with the most common form of liver cancer.

Pharvaris (NASDAQ:PHVS) is moving toward its first regulatory filing in the first half of 2026, supported by a strong cash position and pivotal clinical successes for its lead candidate, deucrictibant.

Merck (NYSE:MRK) has officially moved its lead ophthalmology candidate into late-stage development, initiating a pivotal Phase 2b/3 trial for MK-8748 just two years after the pharmaceutical giant’s $3 billion acquisition of EyeBio.

Lindsay (NYSE:LNN) reported a sharp decline in second-quarter profitability as a contraction in both its agricultural and infrastructure segments weighed on the top line, leading to a more than 50% drop in net earnings.

Trimble (NASDAQ:TRMB) has moved to deepen its artificial intelligence capabilities within the construction sector, announcing an agreement to acquire Document Crunch, a provider of AI-powered contract intelligence and risk management tools.

AirSculpt Technologies (NASDAQ:AIRS), a national provider of body contouring procedures, reported its fourth-quarter and full-year fiscal 2025 financial results.

Transocean (NYSE:RIG) has fortified its financial position through a dual-track strategy of aggressive backlog expansion and balance sheet deleveraging, announcing approximately $1 billion in new contract awards alongside the full retirement of a high-interest bond series.

Acuity Brands (NYSE:AYI) reported a surge in second-quarter profitability and rewarded shareholders with an 18% dividend hike, as the company’s expansion into intelligent infrastructure compensated for a leaner performance in its core lighting segment.